Pirker et al. 1 have published the results of a multinational phase III trial (FLEX; First-Line Erbitux in Lung Cancer) that randomly assigned 1,125 patients with chemotherapy-naive, EGFR ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...

Professor Virginia Harrison, EGFR Positive UK, said: “For people undergoing treatment for lung cancer, maintaining quality of life is so important, but it can be challenging. The development of ...

This year, additional data will come out for all five drugs, except Breyanzi, that could assist in life cycle management ... non-small cell lung cancer; an EGFR x HER3 antibody-drug conjugate ...

GFR continues to grow and they added seven new positions at GFR in this budget cycle.

In LAURA Phase III trial, TAGRISSO continues to demonstrate improved overall survival trend in unresectable, Stage III setting SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib ...